$ALIM News

Last published 1y ago

1y agoALIMApproval of Iluvien, Nda #201923 (Labeling)FDA Approved DrugsApproval Date: 03/12/2025; Drug Name: Iluvien, Nda #201923; Active Ingredients: FLUOCINOLONE ACETONIDE; Company: Alimera Sciences Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 201923
2y agoALIM ANIPANI Pharmaceuticals, Inc. Completes Acquisition of Alimera SciencesGlobeNewswireStrengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant
2y agoALIM ANIPANI Pharmaceuticals Initiates Closing of Acquisition of Alimera SciencesGlobeNewswirePRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced
2y agoALIM ANIPANI Pharmaceuticals and Alimera Sciences Announce Closing Date of MergerBusiness WireANI and Alimera Scheduled the Closing for September 16, 2024 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have
2y agoALIM ANIPANI Pharmaceuticals and Alimera Sciences Announce Closing Date of MergerGlobeNewswirePRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they
2y agoALIM ANIPANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera SciencesGlobeNewswirePRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (NASDAQ:ANIP) today provided an update on the status of the completion of its previously announced acquisition of
2y agoALIM ANIPAlimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger AgreementBusiness WireAlimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholders Approved Merger Agreement on September 4, Clearing Last
2y agoALIMAlimera Sciences Reports Second Quarter 2024 ResultsGlobeNewswireNet Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024
2y agoUMBF ALIM TBNK BESTKuehn Law Encourages UMBF, ALIM, TBNK, and BEST Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoALIMALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI PharmaceuticalsGlobeNewswireMONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera") to ANI Pharmaceuticals
2y agoALIM ANIPANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera SciencesGlobeNewswireConference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial
2y agoALIMAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
2y agoALIMAlimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoALIMAlimera Sciences Reports First Quarter 2024 ResultsGlobeNewswireNet Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.
2y agoALIMAlimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesGlobeNewswireATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
2y agoALIMAlimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateGlobeNewswireATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
2y agoALIMAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
2y agoALIMAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkGlobeNewswireATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with
2y agoALIMAlimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoALIMAlimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsGlobeNewswireQ4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences,
2y agoALIMAlimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate UpdateGlobeNewswireATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
2y agoALIMThe UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®GlobeNewswireATLANTA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
2y agoALIMAlimera Completes Recruitment for the Synchronicity StudyGlobeNewswireATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
2y agoALIMAlimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
2y agoALIMAlimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
3y agoALIMAlimera Appoints Maggie A. Pax to Its Board of DirectorsGlobeNewswireATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of OphthalmologyGlobeNewswireATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Sciences Reports Third Quarter 2023 ResultsGlobeNewswireNet Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ATLANTA, Oct. 26, 2023
3y agoALIMAlimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate UpdateGlobeNewswireATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual CongressGlobeNewswireATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Sciences Appoints Jason Werner as Chief Operating OfficerGlobeNewswireATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with
3y agoALIMAlimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireATLANTA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Sciences Reports Second Quarter 2023 ResultsGlobeNewswireAlimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022Global End User Demand
3y agoALIMAlimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate UpdateGlobeNewswireATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Completes Recruitment for its Landmark NEW DAY StudyGlobeNewswireATLANTA, May 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Acquires U.S. Commercial Rights to YUTIQ®GlobeNewswireExpected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024 Leverages Alimera's
3y agoALIMAlimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ETGlobeNewswireATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Sciences Reports First Quarter 2023 ResultsGlobeNewswireConsolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and Corporate Update Conference Call Cancelled ATLANTA, May 15, 2023
3y agoALIMAlimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate UpdateGlobeNewswireATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Data to be Featured in Scientific Programming at Upcoming Annual CongressGlobeNewswireATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with
3y agoALIMAlimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic CountriesGlobeNewswireATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with
3y agoALIMAlimera Sciences Announces 2022 Financial Results and Business UpdateGlobeNewswire• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility
3y agoALIMAlimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan FacilityGlobeNewswireRepurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000Completes $12 million private placement of preferred stock and warrants with conversion price and exercise
3y agoALIMAlimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate UpdateGlobeNewswireATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Appoints Roger Sawhney, M.D. to Its Board of DirectorsGlobeNewswireATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®GlobeNewswireATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
3y agoALIMAlimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial OfficerGlobeNewswireATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with
3y agoALIMAlimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan AgreementGlobeNewswireATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with
3y agoALIMAlimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® AdministrationGlobeNewswireATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with
3y agoALIMAlimera Sciences Announces Third Quarter 2022 Financial ResultsGlobeNewswireConsolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency Fluctuations Excluding Fluctuations in